This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Prescribing Information for SARCLISA® (isatuximab) can be found via the Product Card at the bottom of the page.

In this video, you'll learn about

A case study presented by Dr Ramasamy of a 70 year old RRMM patient who presented with bone pain, fatigue and was ultra high risk. This case study highlights the disease, treatment and patient related factors which led to the decision to prescribe SARCLISA® + Pd at 4th Line.

Overview of SARCLISA®

Find out more about SARCLISA® + Pd efficacy and safety data and dosing information

Dosing and Administration Guide

Download a handy guide to SARCLISA dosing and administration information.

Patient Booklet

Download SARCLISA® patient information.

Get in touch with the Oncology Team

Relapsed Refractory Multiple Myeloma Product


Prescribing Information GB


MAT-XU-2202578 (v2.0)
Date of preparation: August 2023

MAT-XU-2202568 (v1.0)
Date of Preparation: September 2023 

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.